CZO.V - Ceapro Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.3800
-0.0150 (-3.80%)
As of 11:02AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3950
Open0.3800
Bid0.3800 x 0
Ask0.3950 x 0
Day's Range0.3800 - 0.3800
52 Week Range0.3100 - 0.5400
Volume10,500
Avg. Volume20,667
Market Cap29.278M
Beta (3Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateNov 21, 2017 - Nov 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • What Percentage Of Ceapro Inc. (CVE:CZO) Shares Do Insiders Own?
    Simply Wall St.11 days ago

    What Percentage Of Ceapro Inc. (CVE:CZO) Shares Do Insiders Own?

    If you want to know who really controls Ceapro Inc. (CVE:CZO), then you'll have to look at the makeup of its share...

  • GlobeNewswirelast month

    Ceapro Announces Results of 2019 Shareholders’ Meeting

    EDMONTON, Alberta, June 10, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.

  • GlobeNewswire2 months ago

    Ceapro Presents Positive Results from Avenanthramides Study at the 2019 American Society of Sports Medicine Meeting

    Ceapro Inc. (CZO.V) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented very promising data from its collaboration study of the immunoregulatory effect of oat avenanthramides during downhill running in young men and women at the Annual World Congress of the American College of Sports Medicine (ACSM), held May 28-June 1, 2019 in Orlando, Florida. The Company previously announced positive results on the anti-inflammatory properties of avenanthramides at the American Society for Nutrition’s inaugural flagship meeting, Nutrition 2018, which showed that oat avenanthramides supplementation reduces circulatory inflammation and inhibits expressions of chemokines and adhesion molecules.

  • GlobeNewswire2 months ago

    Ceapro Inc. Commences Patient Enrollment in First-in-Human Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has commenced patient enrollment in its comparison study evaluating high-medium molecular weight beta glucan as an add-on therapy to statins in subjects with hyperlipidemia. “We are pleased with the progress of this important study and believe that it represents a significant milestone for the Company as we continue our transition towards becoming a biopharmaceutical company.

  • GlobeNewswire2 months ago

    Ceapro Inc. Reports 2019 First Quarter Financial Results and Highlights

    - Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development.

  • GlobeNewswire2 months ago

    Ceapro Inc. Announces Receipt of Site License from Health Canada

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that both of its two Alberta-based bioprocessing plants, located in Leduc and Edmonton, have received a Site License from the Health Canada Natural and Non-Prescription Health Products Directorate. This license enables the Company to fabricate, package, label, release and distribute final products.

  • Does Ceapro Inc.'s (CVE:CZO) CEO Pay Compare Well With Peers?
    Simply Wall St.3 months ago

    Does Ceapro Inc.'s (CVE:CZO) CEO Pay Compare Well With Peers?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Gilles Gagnon became the CEO of Ceapro Inc. (CVE:CZO) in 2012. This report will, first, ex...

  • GlobeNewswire3 months ago

    Ceapro Inc. to Present at the ThinkEquity Conference in New York City

    EDMONTON, Alberta, April 24, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.

  • GlobeNewswire3 months ago

    Ceapro Inc. Announces Positive Key Findings from Three Oral Presentations Given at European Meeting on Supercritical Fluids

    EDMONTON, Alberta, April 15, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.

  • GlobeNewswire3 months ago

    Ceapro Inc. Reports Fourth Quarter and Full Year 2018 Results and Highlights

    – 2018 marked by Company’s catalytic pivot from contract manufacturer tobiopharmaceutical company and validation of Ceapro’s dedication to innovation – EDMONTON, Alberta, April.

  • GlobeNewswire4 months ago

    Ceapro Announces Acceptance of Abstract for Presentation at the 2019 American College of Sports Medicine Annual Meeting

    EDMONTON, Alberta, March 27, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.

  • GlobeNewswire4 months ago

    Ceapro Inc. Announces Issuance of Indian Patent Application for Enabling Pressurized Gas eXpanded (PGX) Technology

    Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Office of the Controller General of Patents, Design and Trademarks, India has issued the Company Patent No. 305103 entitled, “Supercritical Fluid Treatment of High Molecular Weight Biopolymers,” related to its Pressurized Gas eXpanded (“PGX”) technology.

  • GlobeNewswire5 months ago

    Ceapro Inc. Announces Three Abstracts Selected for Oral Presentation at the 17th European Meeting on Supercritical Fluids (EMSF 2019)

    EDMONTON, Alberta, Feb. 26, 2019 -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.

  • GlobeNewswire6 months ago

    Ceapro Announces 2019 Management Team and Grant of Stock Options and Restricted Share Units

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) and restricted share units (“RSUs”) to all employees, officers and directors of the Company. Options to purchase 420,000 common shares were granted pursuant to the Company’s Stock Option Plan, with an exercise price of $0.38.5 per common share. Each grant vests in three equal instalments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant.

  • GlobeNewswire7 months ago

    Ceapro Inc. to Present at Biotech Showcase™ 2019

    For more information about the conference, please click here to visit the conference website. A live audio webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website (www.ceapro.com).

  • GlobeNewswire7 months ago

    Ceapro Inc. Presents PGX Technology at the Society of Cosmetic Chemists’ 72nd Annual Scientific Meeting and Technology Showcase

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Paul Moquin, Ph.D., Ceapro’s Director of Scientific Affairs and New Business Development, presented the poster titled, “PGX Technology: a disruptive green platform technology to generate tuneable nanoporous water-soluble biopolymer delivery systems for bioactives,” at the Society of Cosmetic Chemists’ 72nd Annual Scientific Meeting & Technology Showcase being held this week in New York, NY.

  • Could Ceapro Inc’s (CVE:CZO) Investor Composition Influence The Stock Price?
    Simply Wall St.8 months ago

    Could Ceapro Inc’s (CVE:CZO) Investor Composition Influence The Stock Price?

    A look at the shareholders of Ceapro Inc (CVE:CZO) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...

  • GlobeNewswire8 months ago

    Ceapro Inc. Reports 2018 Third Quarter and Nine-Month Financial Results and Operational Highlights

    EDMONTON, Alberta, Nov. 21, 2018 --  Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization.

  • GlobeNewswire8 months ago

    Ceapro Inc. Announces Completion of Successful Audits by Major Customers

    Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company’s new Edmonton-based facility fully complies with recognized quality management systems used by major customers. “The design, construction and implementation of our customized equipment and facilities for this engineering project represented a major undertaking for a Company like Ceapro.